Copyright Reports & Markets. All rights reserved.

Global Next Generation Cancer Diagnostics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
      • 1.4.2 Next Generation Sequencing
      • 1.4.3 qPCR & Multiplexing
      • 1.4.4 DNA Microarrays
      • 1.4.5 Other
    • 1.5 Market by Application
      • 1.5.1 Global Next Generation Cancer Diagnostics Market Share by Application: 2020 VS 2026
      • 1.5.2 Hospitals
      • 1.5.3 Clinics
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends by Regions

    • 2.1 Next Generation Cancer Diagnostics Market Perspective (2015-2026)
    • 2.2 Next Generation Cancer Diagnostics Growth Trends by Regions
      • 2.2.1 Next Generation Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
      • 2.2.2 Next Generation Cancer Diagnostics Historic Market Share by Regions (2015-2020)
      • 2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
    • 2.3 Industry Trends and Growth Strategy
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis
      • 2.3.5 Next Generation Cancer Diagnostics Market Growth Strategy
      • 2.3.6 Primary Interviews with Key Next Generation Cancer Diagnostics Players (Opinion Leaders)

    3 Competition Landscape by Key Players

    • 3.1 Global Top Next Generation Cancer Diagnostics Players by Market Size
      • 3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2015-2020)
      • 3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2015-2020)
      • 3.1.3 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.2 Global Next Generation Cancer Diagnostics Market Concentration Ratio
      • 3.2.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
      • 3.2.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2019
    • 3.3 Next Generation Cancer Diagnostics Key Players Head office and Area Served
    • 3.4 Key Players Next Generation Cancer Diagnostics Product Solution and Service
    • 3.5 Date of Enter into Next Generation Cancer Diagnostics Market
    • 3.6 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type (2015-2026)

    • 4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2015-2020)
    • 4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2021-2026)

    5 Next Generation Cancer Diagnostics Breakdown Data by Application (2015-2026)

    • 5.1 Global Next Generation Cancer Diagnostics Market Size by Application (2015-2020)
    • 5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2021-2026)

    6 North America

    • 6.1 North America Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 6.2 Next Generation Cancer Diagnostics Key Players in North America (2019-2020)
    • 6.3 North America Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 6.4 North America Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    7 Europe

    • 7.1 Europe Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 7.2 Next Generation Cancer Diagnostics Key Players in Europe (2019-2020)
    • 7.3 Europe Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 7.4 Europe Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    8 China

    • 8.1 China Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 8.2 Next Generation Cancer Diagnostics Key Players in China (2019-2020)
    • 8.3 China Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 8.4 China Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    9 Japan

    • 9.1 Japan Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 9.2 Next Generation Cancer Diagnostics Key Players in Japan (2019-2020)
    • 9.3 Japan Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 9.4 Japan Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    10 Southeast Asia

    • 10.1 Southeast Asia Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 10.2 Next Generation Cancer Diagnostics Key Players in Southeast Asia (2019-2020)
    • 10.3 Southeast Asia Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 10.4 Southeast Asia Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    11 India

    • 11.1 India Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 11.2 Next Generation Cancer Diagnostics Key Players in India (2019-2020)
    • 11.3 India Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 11.4 India Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    12 Central & South America

    • 12.1 Central & South America Next Generation Cancer Diagnostics Market Size (2015-2020)
    • 12.2 Next Generation Cancer Diagnostics Key Players in Central & South America (2019-2020)
    • 12.3 Central & South America Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
    • 12.4 Central & South America Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

    13 Key Players Profiles

    • 13.1 Cepheid
      • 13.1.1 Cepheid Company Details
      • 13.1.2 Cepheid Business Overview and Its Total Revenue
      • 13.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
      • 13.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2015-2020))
      • 13.1.5 Cepheid Recent Development
    • 13.2 Koninklijke Philips N.V
      • 13.2.1 Koninklijke Philips N.V Company Details
      • 13.2.2 Koninklijke Philips N.V Business Overview and Its Total Revenue
      • 13.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
      • 13.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.2.5 Koninklijke Philips N.V Recent Development
    • 13.3 F. Hoffmann-La Roche Ltd
      • 13.3.1 F. Hoffmann-La Roche Ltd Company Details
      • 13.3.2 F. Hoffmann-La Roche Ltd Business Overview and Its Total Revenue
      • 13.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
      • 13.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.3.5 F. Hoffmann-La Roche Ltd Recent Development
    • 13.4 Qiagen
      • 13.4.1 Qiagen Company Details
      • 13.4.2 Qiagen Business Overview and Its Total Revenue
      • 13.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
      • 13.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.4.5 Qiagen Recent Development
    • 13.5 Novartis AG
      • 13.5.1 Novartis AG Company Details
      • 13.5.2 Novartis AG Business Overview and Its Total Revenue
      • 13.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
      • 13.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.5.5 Novartis AG Recent Development
    • 13.6 Abbott
      • 13.6.1 Abbott Company Details
      • 13.6.2 Abbott Business Overview and Its Total Revenue
      • 13.6.3 Abbott Next Generation Cancer Diagnostics Introduction
      • 13.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.6.5 Abbott Recent Development
    • 13.7 Thermo Fisher Scientific
      • 13.7.1 Thermo Fisher Scientific Company Details
      • 13.7.2 Thermo Fisher Scientific Business Overview and Its Total Revenue
      • 13.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
      • 13.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.7.5 Thermo Fisher Scientific Recent Development
    • 13.8 Opko Health
      • 13.8.1 Opko Health Company Details
      • 13.8.2 Opko Health Business Overview and Its Total Revenue
      • 13.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
      • 13.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.8.5 Opko Health Recent Development
    • 13.9 Myriad Genetics
      • 13.9.1 Myriad Genetics Company Details
      • 13.9.2 Myriad Genetics Business Overview and Its Total Revenue
      • 13.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
      • 13.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.9.5 Myriad Genetics Recent Development
    • 13.10 Agilent Technologies
      • 13.10.1 Agilent Technologies Company Details
      • 13.10.2 Agilent Technologies Business Overview and Its Total Revenue
      • 13.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
      • 13.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 13.10.5 Agilent Technologies Recent Development
    • 13.11 GE Healthcare
      • 10.11.1 GE Healthcare Company Details
      • 10.11.2 GE Healthcare Business Overview and Its Total Revenue
      • 10.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
      • 10.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.11.5 GE Healthcare Recent Development
    • 13.12 PerkinElmer
      • 10.12.1 PerkinElmer Company Details
      • 10.12.2 PerkinElmer Business Overview and Its Total Revenue
      • 10.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
      • 10.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.12.5 PerkinElmer Recent Development
    • 13.13 Genomic Health
      • 10.13.1 Genomic Health Company Details
      • 10.13.2 Genomic Health Business Overview and Its Total Revenue
      • 10.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
      • 10.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.13.5 Genomic Health Recent Development
    • 13.14 Illumina
      • 10.14.1 Illumina Company Details
      • 10.14.2 Illumina Business Overview and Its Total Revenue
      • 10.14.3 Illumina Next Generation Cancer Diagnostics Introduction
      • 10.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.14.5 Illumina Recent Development
    • 13.15 Hologic
      • 10.15.1 Hologic Company Details
      • 10.15.2 Hologic Business Overview and Its Total Revenue
      • 10.15.3 Hologic Next Generation Cancer Diagnostics Introduction
      • 10.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.15.5 Hologic Recent Development
    • 13.16 Almac Group
      • 10.16.1 Almac Group Company Details
      • 10.16.2 Almac Group Business Overview and Its Total Revenue
      • 10.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
      • 10.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.16.5 Almac Group Recent Development
    • 13.17 Janssen Global Services
      • 10.17.1 Janssen Global Services Company Details
      • 10.17.2 Janssen Global Services Business Overview and Its Total Revenue
      • 10.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
      • 10.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.17.5 Janssen Global Services Recent Development
    • 13.18 Sysmex Corporation
      • 10.18.1 Sysmex Corporation Company Details
      • 10.18.2 Sysmex Corporation Business Overview and Its Total Revenue
      • 10.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
      • 10.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
      • 10.18.5 Sysmex Corporation Recent Development

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
        • 15.1.2 Data Source
      • 15.2 Disclaimer

      This report focuses on the global Next Generation Cancer Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Next Generation Cancer Diagnostics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Cepheid
      Koninklijke Philips N.V
      F. Hoffmann-La Roche Ltd
      Qiagen
      Novartis AG
      Abbott
      Thermo Fisher Scientific
      Opko Health
      Myriad Genetics
      Agilent Technologies
      GE Healthcare
      PerkinElmer
      Genomic Health
      Illumina
      Hologic
      Almac Group
      Janssen Global Services
      Sysmex Corporation

      Market segment by Type, the product can be split into
      Next Generation Sequencing
      qPCR & Multiplexing
      DNA Microarrays
      Other
      Market segment by Application, split into
      Hospitals
      Clinics
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Next Generation Cancer Diagnostics status, future forecast, growth opportunity, key market and key players.
      To present the Next Generation Cancer Diagnostics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by type, market and key regions.

      In this study, the years considered to estimate the market size of Next Generation Cancer Diagnostics are as follows:
      History Year: 2015-2019
      Base Year: 2019
      Estimated Year: 2020
      Forecast Year 2020 to 2026
      For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now